Jupiter Topco LLC Makes New $55.39 Million Investment in Repligen Corporation $RGEN

Jupiter Topco LLC purchased a new stake in Repligen Corporation (NASDAQ:RGEN) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 406,001 shares of the biotechnology company’s stock, valued at approximately $55,393,000. Jupiter Topco LLC owned about 0.72% of Repligen at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of RGEN. Price T Rowe Associates Inc. MD boosted its stake in Repligen by 31.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock worth $753,603,000 after acquiring an additional 1,091,683 shares during the last quarter. United Capital Financial Advisors LLC bought a new stake in Repligen in the third quarter valued at approximately $368,387,000. Opti Capital Management LP acquired a new stake in Repligen in the fourth quarter worth $2,399,209,000. Wasatch Advisors LP raised its holdings in Repligen by 27.9% in the second quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock worth $216,974,000 after purchasing an additional 346,720 shares during the period. Finally, Maverick Capital Ltd. acquired a new position in shares of Repligen in the 1st quarter valued at $178,946,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.60% of the company’s stock.

Repligen Trading Up 1.0%

NASDAQ:RGEN opened at $182.03 on Friday. The company has a market cap of $10.27 billion, a P/E ratio of 249.36, a price-to-earnings-growth ratio of 3.29 and a beta of 1.03. Repligen Corporation has a twelve month low of $100.99 and a twelve month high of $188.73. The business has a 50 day moving average price of $151.11 and a two-hundred day moving average price of $132.79. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. The company had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm’s revenue was up 11.9% compared to the same quarter last year. During the same period last year, the company earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, analysts expect that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on RGEN. Citigroup upgraded shares of Repligen to a “buy” rating in a research report on Tuesday, July 7th. Barclays lifted their target price on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Jefferies Financial Group reissued a “hold” rating and issued a $142.00 target price on shares of Repligen in a research note on Tuesday, May 5th. Wells Fargo & Company increased their price target on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. Finally, Zacks Research upgraded Repligen from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 30th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, Repligen has a consensus rating of “Buy” and a consensus price target of $166.43.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.